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CASE REVIEW
An expanding intracerebral haematoma
Peter Birkeland senior clinical fellow 1 2, Lisbeth Høgedal staff radiologist 3, Frantz Poulsen senior
consultant 2 4
1King’s College Hospital, Department of Neurosurgery, London SE5 9RS, UK; 2Department of Neurosurgery, Odense University Hospital, Odense,
Denmark; 3Department of Radiology, Odense University Hospital; 4Institute of Clinical Research, University of Southern Denmark, Odense
A 44 year old man presented to the emergency department with
a sudden onset headache. He had nomedical history of note and
took no drugs. Urgent computed tomography of the head was
performed (fig 1). A repeat scan (eight minutes later) was
performed after administration of intravenous contrast (OptiRay)
(fig 2). Upon return from the radiology department, he
developed left sided hemiplegia. His blood pressure was 179/90
mm Hg. After another 46 minutes, computed tomography (fig
3) with angiography (not shown) was performed; no abnormal
vessels were seen. Blood tests did not show an underlying
coagulopathy. He subsequently deteriorated to localising to pain
and making incomprehensible sounds to pain without opening
his eyes (Glasgow coma score 8). His pupils remained equal
and reactive to light.
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Fig 1 The patient’s initial computed tomogram of the head
Fig 2 Repeat computed tomogram (eight minutes later)
after administration of intravenous contrast
Fig 3 Repeat computed tomogram (54 minutes after the
first)
The sequence of scans (figs 1-3) depicts an expanding
intracerebral haematoma.
Questions
1. What causes of this bleed should be considered?
2. How should blood pressure be managed in patients with
acute intracerebral haemorrhage?
3. When should surgical evacuation be considered?
4. What other management options could be considered?
5. How common is haematoma expansion?
Answers
1. What causes of this bleed should be
considered?
Short answer
Aneurysmal subarachnoid haemorrhage should first be suspected
in patients with a history of sudden onset headache. However,
in this case the initial scan shows a small haematoma in the
right basal ganglia rather than a subarachnoid haemorrhage. In
patients with haemorrhage in the basal ganglia hypertension is
the most common cause. Other causes include ruptured
arteriovenous malformation, cavernoma, and tumour related
haemorrhage.
Discussion
Aneurysmal subarachnoid haemorrhage should be at the top of
the list of differential diagnoses in patients with a history of
sudden onset headache, but if a haematoma originating from
the right basal ganglia is detected there is no need for a lumbar
puncture to rule it out. The sequence of scans shows a large
deep seated haemorrhage originating from the right basal
ganglia, which is a common site for hypertensive haemorrhages.
Because the first computed tomogram (fig 1) did not suggest
an underlying lesion, the haemorrhage is probably caused by
previously unrecognised hypertension and the diagnosis is
probably primary (hypertensive) intracerebral haemorrhage.
Other common sites for hypertensive haemorrhages are the
thalamus and cerebellum. Differential diagnoses include
bleeding related to a micro- arteriovenous malformation,
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cavernoma, or tumour. A contrast enhanced computed tomogram
may not visualise an underlying tumour, and a computed
tomogram or catheter angiogrammay not detect an arteriovenous
malformation owing to the mass effect of the haematoma. If
there is no history of hypertension or the haematoma has an
atypical location, the patient will need further investigation with
interval magnetic resonance imaging or catheter angiography
(or both) once the haematoma has resolved. Amyloid angiopathy
is an unlikely cause in this case because it usually manifests as
lobar haemorrhages in older people.
2. How should blood pressure be managed
in patients with acute intracerebral
haemorrhage?
Short answer
Consider lowering systolic blood pressure to 140 mm Hg with
a view to limiting haematoma expansion and improving
outcome; however, there is limited evidence on which to base
such a decision.
Discussion
Blood pressure often increases after haemorrhagic stroke. The
rationale for lowering blood pressure is to limit the expansion
of the haematoma and avoid an unfavourable outcome, but such
an effect remains to be proved. American Heart
Association/American Stroke Association recommendations
state that in patients with systolic blood pressure of 150-220
mm Hg and without contraindications to acute blood pressure
treatment, acute lowering of blood pressure to 140 mm Hg is
safe and can improve functional outcomes.1 If systolic blood
pressure is above 220 mm Hg, it may be reasonable to reduce
blood pressure with a continuous intravenous infusion.
Contraindications to acute lowering of blood pressure include
increased intracranial pressure. Symptoms and signs of increased
intracranial pressure are headaches, vomiting, and papilloedema
(although papilloedema does not develop acutely) as well as
Cushing’s response (hypertension, bradycardia, and slow
irregular breathing).
Two randomised controlled trials have investigated whether
rapid lowering of blood pressure with a target systolic pressure
of less than 140mmHgwould improve outcomes. INTERACT2
(Intensive Blood Pressure Reduction in Acute Cerebral
Haemorrhage Trial 2) randomised 2839 patients with a
spontaneous supratentorial intracerebral haemorrhage and raised
systolic blood pressure within six hours of stroke onset to
aggressive blood pressure reduction or blood pressure
management with a target systolic blood pressure less than 180
mm Hg.2 Blood pressure was lowered by using agents of the
physician’s choice, depending on local availability.
INTERACT2 did not show that aggressive blood pressure
reduction resulted in a better primary outcome (death or major
disability). The second trial, ATACH II (Antihypertensive
Treatment of Acute Cerebral Haemorrhage II), differed from
INTERACT2 in several ways.3 The most notable differences
were that treatment had to be started within three hours of the
onset of stroke and the recommended drug was intravenous
nicardipine. This trial is still recruiting.
3. When should surgical evacuation be
considered?
Short answer
Surgery should not be considered at an early stage. In case of
further deterioration, such as ipsilateral third nerve palsy
suggesting impending transtentorial herniation, surgery may be
undertaken at the discretion of a neurosurgeon to save life.
Discussion
The STICH (international Surgical Trial in Intracerebral
Haemorrhage) trials were designed to answer the question of
whether early surgery is beneficial. The first STICH trial, which
investigated whether early surgery would improve outcome in
spontaneous supratentorial haematomas, found no overall benefit
from early surgery comparedwith initial conservative treatment.4
The STICH 2 trial excluded patients with intraventricular
haemorrhages and included only those with a lobar haemorrhage
less than 1 cm from the cortical surface (readily accessible
surgical target).5 The STICH 2 trial largely confirmed the
conclusions from the first STICH trial, that surgery should
probably not be considered at an early stage. However, if the
patient is likely to die from the mass effect of the haematoma,
surgerymay be undertaken even though it has no proved benefit.
The STICH trials did not look at this clinical situation. Patients
should have hourly neurological observations and if deterioration
occurs further discussion with a neurosurgeon is warranted.
Whenever possible the decision to proceed to surgery should
be discussed with the patient, or, if this is not possible, the
patient’s next of kin, to promote shared decisionmaking. Factors
that may favour a decision to proceed to surgery include
in-hospital clinical deterioration, the need for intubation,
superficially located haematoma, and absence of serious
comorbidities.
4. What other management options could be
considered?
Short answer
Treatment is largely supportive and the patient should be
admitted to a dedicated stroke unit.
Discussion
The patient should be admitted to a dedicated stroke unit.
Treatment is largely supportive, because no specific medical or
surgical intervention has been shown to improve survival and
outcome. If there is evidence of intracranial hypertension, an
algorithm borrowed from traumatic brain injury guidelines can
be considered.6
The use of tranexamic acid is currently being investigated as a
means to limit haematoma expansion and improve outcome.7
A spot sign (a focus of contrast enhancement within a
haematoma on a computed tomography angiogram) is a predictor
of haematoma expansion,8 and it be a useful as a tool to select
patients who are likely to benefit from this intervention.9
Recombinant factor VIIa reduced haematoma growth in a phase
III randomised controlled trial, but it did not improve overall
outcome because patients receiving this factor had a higher risk
of arterial thromboembolic events.10 Recombinant factor VIIa
is therefore not currently used for this indication.
5. How common is haematoma expansion?
Short answer
Substantial haematoma growth occurs in about 40% of patients
with spontaneous intracranial haemorrhage and most often in
the first few hours after stroke.
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Discussion
In a cohort of 103 patients presenting to hospital within three
hours of haemorrhagic stroke, 38% of patients had more than
33% growth in haematoma volume.11 Another study found that
in a cohort of 25 patients presenting within 4.5 hours of a
haemorrhagic stroke, 10 patients had haematoma expansion of
more than 12.5 mL during the first six hours in hospital.12
Although it is appealing to visualise haematoma expansion as
being caused by a continuous bleed from a single vessel, it is
more likely that expansion of the haemorrhage causes shearing
and rupture of neighbouring vessels as a sort of avalanche
effect.13 14
Patient outcome
The patient underwent surgery to remove the haematoma. He
remained intubated, sedated, and on mechanical ventilation for
three weeks. Serial postoperative computed tomograms showed
resolution of the haematoma and subsequent magnetic resonance
imaging of the brain confirmed no underlying vascular disease.
He was transferred to a local rehabilitation unit with a dense
left sided hemiplegia. Nine months after the ictus he was
discharged home and is now able to walk 200 m unaided.
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